论文部分内容阅读
目的探讨CA125、CA724和抑制素A(INH-A)在卵巢癌诊断中的临床应用价值,为提高卵巢癌的诊断率提供依据。方法采用全自动化学发光免疫分析法检测58例卵巢癌患者血清中的CA125、CA724和INH-A水平,并分析3指标单独和联合检查的阳性率及不同临床病理特征(病理分级、临床分期和淋巴结转移情况)的3指标水平,选取同期的60例卵巢良性疾病患者和61例健康体检者作对比。结果卵巢癌组的CA125、CA724和INH-A水平均高于对照组和卵巢良性疾病组(P<0.01);卵巢癌组CA125、CA724、INH-A及3项联合检查的阳性率均高于对照组和卵巢良性疾病组(P<0.01);卵巢癌患者中低分化、Ⅲ+Ⅳ期及有淋巴结转移的CA125、CA724和INH-A水平均高于高分化、Ⅰ+Ⅱ期及无淋巴结转移(P<0.01),低分化的3指标水平均高于中分化(P<0.05)。结论卵巢癌患者血清的CA125、CA724和INH-A水平升高,且与临床病理特征有关,3者联合检测可提高检测阳性率。
Objective To investigate the clinical value of CA125, CA724 and inhibin A (INH-A) in the diagnosis of ovarian cancer and provide the basis for improving the diagnosis rate of ovarian cancer. Methods The serum levels of CA125, CA724 and INH-A in 58 patients with ovarian cancer were detected by using the method of automated chemiluminescence immunoassay. The positive rate and clinical and pathological features of the 3 indexes were analyzed separately (pathological grade, clinical stage and Lymph node metastasis) 3 indicators, select the same period in 60 cases of benign ovarian disease and 61 healthy subjects for comparison. Results The levels of CA125, CA724 and INH-A in ovarian cancer group were significantly higher than those in control group and benign ovarian disease group (P <0.01). The positive rates of CA125, CA724, INH-A and 3 combined tests in ovarian cancer group were higher than Control group and benign ovarian disease group (P <0.01). The levels of CA125, CA724 and INH-A in patients with low differentiation, Ⅲ + Ⅳ and lymph node metastasis were significantly higher than those in well-differentiated, Ⅰ + Ⅱ and non-lymph node Metastasis (P <0.01), poorly differentiated 3 indicators were higher than the moderately differentiated (P <0.05). Conclusion Serum levels of CA125, CA724 and INH-A in patients with ovarian cancer are elevated, which are correlated with the clinicopathological features. The combined detection of the three can increase the detection positive rate.